middl
east
respiratori
syndrom
coronaviru
merscov
novel
beta
coronaviru
may
caus
lethal
respiratori
diseas
antimerscov
serolog
test
includ
enzymelink
immunosorb
assay
elisa
immunofluoresc
assay
ifa
avail
commerci
kit
use
variou
purpos
includ
epidemiolog
investig
evalu
antibodi
kinet
assess
feasibl
convalesc
plasma
infus
therapi
manufactur
instruct
provid
rel
high
cutoff
valu
posit
warrant
specif
deriv
limit
posit
sampl
elisa
igg
euroimmun
germani
mer
patient
sampl
neg
control
previous
conduct
serolog
studi
cutoff
valu
differ
appli
depend
purpos
serolog
test
sever
epidemiolog
studi
appli
low
cutoff
valu
increas
sensit
test
other
follow
manufactur
instruct
also
confirm
merscovinfect
patient
mount
robust
neutral
activ
perform
serolog
test
separ
analyz
depend
purpos
test
predict
neutral
activ
merscovinfect
patient
diagnos
merscov
infect
epidemiolog
surveil
provid
optim
cutoff
valu
depend
purpos
test
evalu
perform
variou
antimerscov
serolog
test
use
serum
sampl
merscovinfect
patient
serum
sampl
rrtpcrneg
merscovexpos
healthcar
personnel
hcp
patient
perform
analysi
includ
sensit
specif
posit
predict
valu
neg
predict
valu
conduct
two
differ
purpos
serolog
test
predict
neutral
activ
merscovinfect
patient
epidemiolog
surveil
merscov
infect
among
merscovexpos
individu
plaqu
reduct
neutral
test
prnt
sputum
realtim
revers
transcriptas
polymeras
chain
reaction
rrtpcr
merscov
use
gold
standard
assess
neutral
activ
diagnos
merscov
infect
respect
merscov
exposur
date
symptom
onset
collect
serum
sampl
clearli
identifi
owe
thorough
contact
investig
monitor
expos
individu
provid
common
point
refer
use
day
post
onset
ill
dpoi
assess
neutral
activ
sinc
symptom
onset
could
clearli
identifi
among
merscovinfect
patient
meanwhil
epidemiolog
surveil
usual
conduct
basi
exposur
event
appli
day
post
exposur
dpex
assess
diagnost
perform
serolog
test
epidemiolog
surveil
compar
perform
serolog
test
depend
serum
collect
time
test
evalu
three
differ
timepoint
regardless
serum
collect
time
dpoi
dpex
dpoi
dpex
korean
mer
outbreak
obtain
serum
sampl
merscov
infect
patient
studi
popul
includ
patient
manag
tertiari
care
univers
hospit
seven
patient
donat
sera
plasma
infus
therapi
serolog
test
merscov
infect
confirm
basi
rrtpcr
assay
target
upstream
e
gene
upe
openread
frame
gene
epidemiolog
investig
data
electron
medic
record
review
obtain
exact
exposur
date
symptom
onset
one
two
serum
sampl
collect
per
week
ill
hospit
followup
serum
sampl
obtain
month
symptom
onset
outpati
clinic
sera
rrtpcrneg
merscovexpos
hcp
patient
use
neg
control
sampl
collect
sampl
store
three
month
test
institut
review
board
samsung
medic
center
approv
present
studi
antimerscov
elisa
igg
iga
euroimmun
germani
base
solubl
merscov
spike
protein
domain
express
cell
sera
test
accord
manufactur
instruct
dilut
secondari
detect
done
peroxidaselabel
antihuman
igg
iga
elisa
igg
initi
test
collect
serum
sampl
serolog
test
includ
elisa
iga
ifa
prnt
select
perform
depend
elisa
igg
use
optic
densiti
od
ratio
cutoff
valu
sputum
rrtpcr
result
tabl
sinc
ifa
igg
limitedli
test
among
rrtpcrneg
popul
diagnost
perform
epidemiolog
surveil
ifa
igg
could
evalu
antimerscov
ifa
igg
igm
euroimmun
perform
slide
carri
vero
cell
infect
full
merscov
sera
test
accord
manufactur
instruct
dilut
ifa
igm
igg
respect
comparison
perform
ifa
igg
elisa
igg
sera
select
titrat
dilut
includ
sera
collect
dpoi
presum
window
period
seroconvers
sera
patient
serial
sampl
least
four
time
tabl
merscov
prnt
perform
previous
describ
predilut
set
seri
defin
lowest
possibl
signific
titer
categor
sampl
posit
cutoff
valu
optim
sensit
specif
analyz
per
od
ratio
ifa
intens
area
curv
auc
calcul
use
receiv
oper
characterist
roc
curv
window
rstudio
boston
usa
use
statist
analys
perform
serolog
test
improv
delay
sampl
time
maxim
sera
collect
dpoi
use
fig
predict
neutral
activ
elisa
igg
ifa
igm
test
show
optim
perform
use
sera
collect
dpoi
cutoff
valu
od
ratio
weeklyposit
ifa
intens
respect
tabl
especi
elisa
igg
show
sensit
specif
time
point
elisa
igg
ifa
igm
exhibit
slightli
lower
perform
area
curv
auc
respect
meanwhil
elisa
iga
show
optim
perform
use
sera
collect
dpoi
cutoff
valu
od
ratio
detail
perform
valu
depend
serum
collect
time
cutoff
valu
present
supplementari
tabl
ifa
igg
show
optim
perform
cutoff
valu
dilut
overal
perform
superior
elisa
igg
supplementari
tabl
diagnos
merscov
infect
elisa
igg
elisa
iga
ifa
igm
test
show
optim
perform
use
sera
collect
dpex
cutoff
valu
od
ratio
od
ratio
weaklyposit
ifa
intens
respect
tabl
valu
rrtpcrneg
merscovexpos
individu
cutoff
valu
discrimin
merscovinfect
noninfect
individu
fig
overal
elisa
igg
show
better
perform
elisa
iga
ifa
igm
diagnos
merscov
infect
auc
respect
sera
collect
dpex
use
perform
serolog
test
improv
delay
sampl
time
maxim
sera
collect
dpex
use
fig
supplementari
tabl
addit
specif
elisa
igg
elisa
iga
ifa
igm
test
regardless
serum
collect
time
cutoff
valu
od
ratio
od
ratio
ifa
intens
respect
neutral
test
gold
standard
method
detect
antivir
antibodi
especi
exhibit
viruskil
function
howev
neutral
test
merscov
readili
perform
worldwid
requir
biosafeti
level
facil
skill
expert
carri
potenti
risk
infect
reduc
risk
workload
previou
antimerscov
serolog
studi
appli
stepwis
approach
use
elisa
ifa
rel
easi
safe
test
make
antimerscov
serolog
test
practic
assess
perform
elisa
ifa
test
two
clinic
purpos
suggest
optim
cutoff
valu
previou
cutoff
valu
posit
provid
diagnosi
merscov
infect
firstli
suggest
cutoff
valu
predict
neutral
activ
present
analysi
elisa
igg
iga
excel
predict
neutral
activ
use
sera
collect
dpoi
auc
respect
note
elisa
igg
show
sensit
specif
time
point
od
ratio
cutoff
valu
predict
neutral
activ
extrem
import
select
donor
recipi
convalesc
plasma
infus
therapi
potenti
treatment
merscov
infect
present
analysi
even
dpoi
supplementari
tabl
collect
sera
neutral
activ
emphas
import
antibodi
test
collect
convalesc
plasma
addit
measur
neutral
activ
also
import
select
recipi
evalu
effect
convalesc
plasma
infus
use
elsia
test
perform
data
present
analysi
evalu
neutral
activ
perform
field
mer
patient
manag
without
delay
diagnos
merscov
infect
use
antimerscov
serolog
test
practic
use
postexposur
epidemiolog
studi
seropreval
investig
endem
region
increas
sensit
elisa
screen
test
sever
epidemiolog
studi
appli
low
cutoff
valu
od
ratio
usual
threefold
valu
neg
control
elisa
igg
od
ratio
depend
studi
site
present
analysi
demonstr
elisa
igg
cutoff
valu
od
ratio
actual
show
optim
perform
high
specif
visual
well
demonstr
fig
elisa
igg
cutoff
valu
od
ratio
optim
discrimin
neg
control
symptomat
infect
group
elisa
iga
ifa
igm
show
inferior
perform
differenti
neg
control
mild
patient
group
asymptomat
patient
group
show
serolog
respons
make
serolog
diagnosi
inapplic
manufactur
instruct
provid
significantli
higher
break
point
mer
diagnosi
warrant
specif
elisa
igg
borderlin
od
ratio
cutoff
posit
howev
demonstr
elisa
igg
exhibit
specif
cutoff
valu
od
ratio
supplementari
tabl
previou
cutoff
valu
od
ratio
show
extrem
low
sensit
therefor
suggest
elisa
igg
od
ratio
new
break
point
merscov
diagnosi
gener
applic
od
ratio
appli
maxim
specif
addit
recommend
take
least
interv
mersexposur
serum
sampl
postexposur
serolog
investig
warrant
seroconvers
unpublish
data
seroconvers
occur
around
third
week
ill
fourth
week
exposur
dpoi
median
rang
dpex
median
rang
ko
et
al
data
review
although
elisa
igg
show
slightli
higher
auc
ifa
igg
supplementari
tabl
number
ifa
test
sampl
suffici
limit
comparison
perform
two
differ
method
howev
perform
elisa
igg
least
inferior
ifa
igg
impli
addit
confirm
ifa
elisa
screen
mandatori
addit
consid
crossreact
serolog
test
coronavirus
perform
mer
diagnosi
could
affect
local
epidemiolog
human
coronaviru
infect
conclus
perform
analysi
use
serum
sampl
form
merscovinfect
patient
elisa
igg
show
optim
perform
predict
neutral
activ
diagnos
merscov
infect
cutoff
valu
od
ratio
respect
perform
analysi
antimerscov
serolog
test
practic
use
field
mer
manag
